Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
The role of the newly discovered cysteine protease, cathepsin K, in osteoporosis and rheumatoid arthritis is reviewed. The current development of cathepsin K inhibitors and their targeted delivery using synthetic polymer carriers are discussed. Future challenges and possible strategies to improve these delivery systems are addressed.
Wang
D
D
Department of Pharmaceutics and Pharmaceutical Chemistry/CCCD, University of Utah, 30 S 2000 E Rm. 301, Salt Lake City, UT 84112, USA.
Li
W
W
Pechar
M
M
Kopecková
P
P
Brömme
D
D
Kopecek
J
J
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D056657:Cathepsin K; D002403:Cathepsins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D011108:Polymers / Q000737:chemistry / Q000627:therapeutic use
D015853:Cysteine Proteinase Inhibitors; D011108:Polymers; D002403:Cathepsins; C534130:CTSK protein, human; D056657:Cathepsin K